GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal ... to US if Trump's pharma tariffs take hold, CEO says ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...

Bearish flow noted in GSK (GSK) Pharma with 6,103 puts trading, or 5x expected. Most active are 3/14 weekly 39.5 puts and Mar-25 41.5 calls, with total volume in those strikes near 5,500 contracts.

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer.

Associate Global Pharmaceutical Analyst at GlobalData. She added that GSK may be getting more bang per buck in terms of its R&D investment, with seven drugs in pre-registration phase compared with ...

GSK’s chief digital and technology officer (CDTO) worked for years at tech giants like Apple and Salesforce before making the switch to the increasingly tech-savvy pharmaceutical sector.